STOCK TITAN

Olema Pharmaceuticals changes name to Olema Oncology

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Olema Pharmaceuticals, Inc. changed its corporate name to Olema Oncology, Inc., effective November 12, 2026, and amended its bylaws to reflect the change. Its common stock continues to trade on The Nasdaq Global Select Market under OLMA.

Effective the same day, the company relocated its principal executive offices from San Francisco to South San Francisco. Stock certificates bearing the former corporate name remain valid.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Palazestrant clinical trials 2 Phase 3 clinical trials The company’s lead product candidate, palazestrant (OP-1250).
OP-3136 clinical study 1 Phase 1 clinical study The company is developing OP-3136, a KAT6 inhibitor.
complete estrogen receptor antagonist (CERAN) medical
"a proprietary, orally available complete estrogen receptor antagonist (CERAN)"
selective estrogen receptor degrader (SERD) medical
"a selective estrogen receptor degrader (SERD)"
KAT6 inhibitor medical
"a potent lysine acetyltransferase 6 (KAT6) inhibitor"
A KAT6 inhibitor is a type of drug that blocks the activity of the KAT6 enzyme, which helps turn certain genes on by adding chemical tags; think of it as dimming a light switch that controls gene programs. Investors care because these inhibitors are being tested as treatments for cancers and other diseases, and clinical progress, safety results, or regulatory decisions can materially affect a company’s future revenue prospects and stock value.
endocrine-driven cancers medical
"our deep understanding of endocrine-driven cancers"
mechanisms of acquired resistance medical
"mechanisms of acquired resistance"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001750284--12-31false0001750284dei:FormerAddressMember2026-11-122026-11-1200017502842026-11-122026-11-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2026

 

 

Olema Oncology, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39712

30-0409740

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

 

365 Oyster Point Blvd., Suite 400

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 415 651-3316

 

Olema Pharmaceuticals, Inc.

780 Brannan Street

San Francisco, California 94103

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

OLMA

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On November 12, 2026, Olema Oncology, Inc. (formerly known as Olema Pharmaceuticals, Inc.) (the “Company”) filed its Eighth Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware to change the Company's corporate name from “Olema Pharmaceuticals, Inc.” to “Olema Oncology, Inc.” (the “Name Change”). The Restated Certificate became effective at 4:01 p.m., Eastern Time, on November 12, 2026.

The Company's Board of Directors (the “Board”) approved the Restated Certificate in accordance with the Delaware General Corporation Law (“DGCL”). Pursuant to the DGCL, stockholder approval was not required to effect the Name Change.

 

In connection with the Name Change, the Board also approved an amendment and restatement of the Company's Amended and Restated Bylaws to reflect the Name Change (the “Restated Bylaws”). The Restated Bylaws became effective upon the effectiveness of the Restated Certificate.

 

The Company's common stock will continue to trade on The Nasdaq Global Select Market under the ticker symbol “OLMA.”

 

The foregoing descriptions of the Restated Certificate and the Restated Bylaws are qualified in their entirety by reference to the Restated Certificate and the Restated Bylaws, copies of which are filed as Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On November 12, 2026, the Company issued a press release announcing the Company's name change, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

Effective November 12, 2026, the Company relocated its principal executive offices from 780 Brannan Street, San Francisco, CA 94103 to 365 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

 

Exhibit No.

Description

3.1

Eighth Amended and Restated Certificate of Incorporation of Olema Oncology, Inc.

3.2

Amended and Restated Bylaws of Olema Oncology, Inc.

99.1

Press Release, dated November 12, 2026, of Olema Oncology, Inc.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

OLEMA ONCOLOGY, INC.

 

 

 

 

Date:

November 12, 2026

By:

/s/ Sean Bohen, M.D., Ph.D.

 

 

 

Sean Bohen, M.D., Ph.D.
President and Chief Executive Officer

 

 


Exhibit 99.1

 

img39466132_0.jpg

 

Olema Oncology Announces Corporate Name Change

 

SAN FRANCISCO, November 12, 2026 (Globe NewsWire) – Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, announced that, effective today, it has changed its corporate name from “Olema Pharmaceuticals, Inc.” to “Olema Oncology, Inc.” pursuant to the Company’s Eighth Amended and Restated Certificate of Incorporation filed with the Secretary of State of Delaware.

 

The Company’s common stock will continue to be listed and trade on the Nasdaq Global Select Market under the ticker symbol “OLMA.” Pursuant to Delaware law, no action was required by stockholders of the Company to effect the name change. Stock certificates reflecting the prior corporate name will continue to be valid.

 

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

 

Media and Investor Relations Contact

Courtney O’Konek

Vice President, Corporate Communications

Olema Oncology

media@olema.com


Filing Exhibits & Attachments

4 documents

Keep reading